Toyonaka-city, Japan Clinical Trials

A listing of Toyonaka-city, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD). Phase 2: To evaluate the efficacy of efavaleukin alfa in subjects with steroid refractory cGVHD as measured by overall response rate (ORR) at 16 …

Research Site
 (9.5 away) Contact site
  • 12 views
  • 12 Jun, 2021
  • +28 other locations
A Study of AZD8233 in Participants With Dyslipidemia.

A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A and Part B. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, …

Research Site
 (4.1 away) Contact site
  • 0 views
  • 07 May, 2021
  • +1 other locations
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor …

Eisai Trial Site #17
 (3.0 away) Contact site
  • 2 views
  • 06 Apr, 2021
  • +16 other locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

ret inhibitor
measurable disease
cancer
systemic therapy
kidney function test
Osaka City General Hospital
 (6.0 away) Contact site
  • 1244 views
  • 14 May, 2021
  • +158 other locations
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. …

metastatic solid tumor
metastasis
breast cancer
primary cancer
solid tumor
Osaka City Hospital Organization Osaka City General Hospital
 (6.0 away) Contact site
  • 0 views
  • 22 May, 2021
  • +70 other locations
A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the …

bone marrow plasma cells
bortezomib
daratumumab
measurable disease
serum calcium
Osaka City University Hospital
 (9.5 away) Contact site
  • 0 views
  • 14 May, 2021
  • +78 other locations
A Phase 1/2 Study Evaluating the Safety Tolerability PK and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Research Site
 (7.2 away) Contact site
  • 472 views
  • 13 Jun, 2021
  • +282 other locations
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

The purpose of the trial is to determine the maximum tolerated dose and/or the recommended phase 2 dose as well as to establish the safety profile of epcoritamab in Japanese patients with Relapsed, Progressive or Refractory B-Cell Lymphomas.

ct scan
monoclonal protein
monoclonal antibodies
measurable disease
antineoplastic
Osaka University Hospital
 (4.1 away) Contact site
  • 0 views
  • 24 May, 2021
  • +20 other locations
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF) Post-polycythemia Vera Myelofibrosis (Post-PV MF) or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, …

Osaka City University Hospital
 (9.5 away) Contact site
  • 0 views
  • 27 Feb, 2021
  • +15 other locations
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase …

flt3 internal tandem duplication
neoadjuvant therapy
serum bilirubin level
induction chemotherapy
idarubicin
Site JP81019
 (6.3 away) Contact site
  • 10 views
  • 13 Jun, 2021
  • +58 other locations